Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

288.35
Delayed Data
As of Jul 27
 +1.31 / +0.46%
Today’s Change
223.02
Today|||52-Week Range
338.51
-5.88%
Year-to-Date
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Jul 27 / Zacks.com - Paid Partner Content
An Investing Overview of the Multiple Sclerosis Market
Jul 26 / MotleyFool.com - Paid Partner Content
5 Undervalued Growth Stocks to Buy Today
Jul 27 / MotleyFool.com - Paid Partner Content
Where Is the Insider Buying?
Jul 25 / TheStreet.com - Paid Partner Content
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Jul 27 / Zacks.com - Paid Partner Content
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
Jul 25 / Zacks.com - Paid Partner Content
Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure
Jul 27 / TheStreet.com - Paid Partner Content
I'm Bullish on Biotechs
Jul 25 / TheStreet.com - Paid Partner Content
5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Jul 26 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
Jul 25 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close287.04
Today’s open286.83
Day’s range286.08 - 288.77
Volume1,458,156
Average volume (3 months)1,857,902
Market cap$62.9B
Dividend yield--
Data as of 07/27/2016

Growth & Valuation

Earnings growth (last year)+24.01%
Earnings growth (this year)+16.67%
Earnings growth (next 5 years)+9.50%
Revenue growth (last year)-3.87%
P/E ratio16.8
Price/Sales7.60
Price/Book6.69

Competitors

 Today’s
change
Today’s
% change
BAXBaxter International...+0.31+0.65%
GILDGilead Sciences+0.74+0.91%
NBIXNeurocrine Bioscienc...+1.20+2.42%
JUNOJuno Therapeutics In...-0.15-0.49%
Data as of 07/27/2016

Financials

Last reporting dateJuly 21, 2016
EPS forecast (this quarter)$4.68
Annual revenue (last year)$9.3B
Annual profit (last year)$3.5B
Net profit margin38.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
George A. Scangos
Chief Scientific Officer &
Executive VP
Spyridon Artavanis-Tsakonas
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs